PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 1193439
PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 1193439
CRISPR and Cas Genes Market size was valued at USD 2,008.3 Million in 2022, expanding at a CAGR of 20.5% from 2023 to 2030.
The identification of CRISPR and Cas genes has led to the development of CRISPR, and Cas systems. The technique is frequently used in research to find novel neurodegenerative disease treatment alternatives. The application of CRISPR-Cas systems in diagnostics and the evaluation of evolutionary analyses in prokaryotes has been made possible by advancements in genome editing.
Market Dynamics
The market for CRISPR and Cas Genes is driven by the rising development in genome editing, and gene discovery. CRISPR and Cas systems have been developed because of the discovery of the CRISPR and Cas genes. In order to discover new therapeutic options for neurodegenerative diseases, the approach is commonly employed in research. Advances in genome editing have allowed for the use of CRISPR-Cas systems in diagnostics and the evaluation of evolutionary analyses in prokaryotes. thus, the increasing demand from diagnostic and therapeutics of new genetic disorders is expected to contribute to market growth.
Further, increasing developments in genome editing technology is another factor boosting the market growth. Data on the mechanism behind the potential of the chRDNA genome-editing method in basic human T cells were given by Caribou Biosciences, Inc. in May 2023. It offers a repeatable and reliable method to increase genome editing's specificity, and it boosts the effectiveness of allogeneic cell treatments. In the upcoming years, it is projected that these advances will fuel the industry's expansion. The demand for gene editing techniques like CRISPR & Cas gene technology has increased as a result of innovative technologies like karyotyping, newborn screening, virus screening, and others. Additionally, the biotechnology sector has seen a rise in the utilisation of CRISPR & Cas gene technology to improve agricultural production through creative breeding techniques.
Segmentation Analysis:
The Global CRISPR and Cas Genes Market is segmented on the basis of Product, Application, End User, and Region.
The market is split into five categories based on Product: kits & enzymes, libraries, design tool, antibodies, and others. The kits & enzymes segment dominates the market. Growing demand for DNA free cas and vector-based cas is mainly contributing to segment growth.
The market is segmented into three categories based on application: clinical, financial, and operational & administrative. The clinical segment dominates the market and is likely to maintain its dominance during the forecast period. This is partly due to a rise in the demand for clinical diagnostics.
The market is segmented into five categories based on end user: biotechnology & pharmaceutical companies, academics & government research institutes, and Contract Research Organizations (CROs). The biotech & pharmaceutical companies segment dominates the market and is likely to maintain its dominance during the forecast period. This is partly due to an increase in the demand for CRISPR and cas genes in biotech development is boosting the segment growth.
Competitive Landscape:
The worldwide market for CRISPR and Cas Genes is significantly fragmented in nature which comprised of large and small-sized market players with few large dominating the global market share. The companies in market emphasize on adopting aggressive strategies to reach out large consumer base. Some of the primary techniques used by corporations to strengthen their reach and expand their market share include new Product launches, partnerships, distribution network development, R&D spending, and mergers and acquisitions.
For instance, in November 2022, GenScript launched a double-stranded DNA service to expand its cell and gene therapy product portfolio using CRISPR & Cas gene technology.
Key features of the study:
This proposed research study on CRISPR and Cas Genes market provides market size (US$ million), compound annual growth rate (CAGR %) and forecast estimation (2023-2030), considering 2022 as the base year
The research report elucidates potential growth opportunities across different segments/countries and explains attractive investment proposition matrix for CRISPR and Cas Genes market
The overall report identifies new investment opportunities, challenges faced by established players, and growth factors to sustain in the CRISPR and Cas Genes market
Impact of COVID-19 on CRISPR and Cas Genes market size, forecast, CAGR, and market dynamics are discussed in detail under the research scope. Detailed insight on CRISPR and Cas Genes market post-COVID will also be covered.
In order to give the users of this report a comprehensive view on the CRISPR and Cas Genes market, we have also included competitive landscape and key innovator analysis for the CRISPR and Cas Genes market.
The study encompasses a growth prospect mapping analysis, wherein all the industry segments are benchmarked based on their market size, growth rate and attractiveness.
The report offers detailed company profiling featuring major market participants which will help users to understand their financial information and strategic initiatives of players operating in the CRISPR and Cas Genes market.
In addition, the report also unveil the important acquisitions & mergers, collaborations & joint ventures, new launch, research & development, regional expansion of major participants involved in the market on global as well as regional level.
The global CRISPR and Cas Genes market report primarily caters to various stakeholders in this industry including suppliers, investors, new entrants, distributors, and financial analysts
SCOPE OF THE REPORT
The scope of this report covers the market by its major segments, which include as follows:
GLOBAL CRISPR AND CAS GENES MARKET KEY PLAYERS
AstraZeneca plc
Addgene
Caribou Biosciences, Inc.
Cellectis, CRISPR Therapeutics
Editas Medicine, Inc.
eGenesis
F. Hoffmann-La Roche Ltd.
Horizon Discovery Group plc
GenScript
Danaher Corp.
Intellia Therapeutics, Inc.
Lonza
Merck KGaA
Intellia Therapeutics, Inc.
Takara Bio Inc.
Thermo Fisher Scientific, Inc.
Synthego
Mammoth Biosciences
Inscripta, Inc.
Cibus
Beam Therapeutics
PLANTeDIT
GLOBAL CRISPR AND CAS GENES MARKET, BY PRODUCT
Kits & enzymes
Libraries
Design tool
Antibodies
Others
GLOBAL CRISPR AND CAS GENES MARKET, BY APPLICATION
Clinical
Financial
Operational & administrative
GLOBAL CRISPR AND CAS GENES MARKET, BY END USER
Biotechnology & pharmaceutical companies
Academics & government research institutes
Contract Research Organizations (CROs)
GLOBAL CRISPR AND CAS GENES MARKET, BY REGION
North America
The U.S.
Canada
Europe
Germany
France
Italy
Spain
United Kingdom
Russia
Netherlands
Sweden
Poland
Rest of Europe
Asia Pacific
India
China
South Korea
Japan
Australia
Thailand
Indonesia
Philippines
Rest of APAC
Latin America
Brazil
Mexico
Argentina
Colombia
Rest of LATAM
The Middle East and Africa
Saudi Arabia
United Arab Emirates
Israel
Turkey
Algeria
Egypt
Rest of MEA